{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:19:09Z","timestamp":1787548749866,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>The therapeutic landscape for primary biliary cholangitis (PBC) with an inadequate response to ursodeoxycholic acid (UDCA) is rapidly evolving. With the recent advent of peroxisome proliferator-activated receptor (PPAR) agonists and ileal bile acid transporter (IBAT) inhibitors, establishing a comparative hierarchy is urgently needed. We aimed to evaluate the relative efficacy, symptomatic relief, and safety of all second-line PBC therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and recent major hepatology congresses (EASL\/AASLD) up to early 2026. We included randomized controlled trials (RCTs) with durations of 12\u201352\u00a0weeks evaluating PPAR agonists (bezafibrate, seladelpar, elafibranor, saroglitazar), farnesoid X receptor (FXR) agonists (obeticholic acid [OCA]), and IBAT inhibitors (linerixibat) against placebo\/UDCA. A frequentist network meta-analysis (NMA) was performed. Outcomes included biochemical response (POISE criteria, reflecting standard 6- to 12-month clinical evaluation timelines), complete alkaline phosphatase (ALP) normalization (\u22641.0x ULN), pruritus improvement (standardized mean difference [SMD]), and safety (serious adverse events [SAEs]). Treatments were ranked using P-scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve RCTs comprising 1,540 patients (therapy lengths 12\u201352\u00a0weeks) were included. For POISE criteria, bezafibrate ranked highest (Odds Ratio [OR] 77.44, 95% CI 8.96\u2013669.51; P-score 0.89). However, for the stringent endpoint of complete ALP normalization, seladelpar 10\u00a0mg was superior (OR 44.12, 95% CI 2.65\u2013733.27; P-score 0.79). Regarding symptomatic relief, seladelpar and linerixibat significantly alleviated pruritus, whereas OCA exacerbated it (SMD +0.50, 95% CI 0.35\u20130.65). Bivariate cluster analyses integrating efficacy, pruritus relief, and SAEs identified seladelpar 10\u00a0mg as possessing the most optimal risk-benefit profile. OCA exhibited the highest discontinuation-free tolerability but lacked robust ALP normalization and anti-pruritic benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The treatment paradigm for UDCA-refractory PBC is shifting towards individualized care. While bezafibrate offers unparalleled potency for POISE criteria, seladelpar 10\u00a0mg provides the most advantageous clinical balance, achieving deep biochemical remission (ALP normalization) alongside profound pruritus relief and a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registeration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=261351<\/jats:ext-link>\n                      , identifier 420261351426.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1859342","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:24:32Z","timestamp":1787545472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, symptoms, and safety of second-line PBC therapies: a network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenbin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of General Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxian","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","first-page":"323","article-title":"Recent advances in the development of targeted therapies for primary biliary cholangitis","volume":"22","author":"Ali","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B6","first-page":"1052","article-title":"Pruritus is common and severe in patients with primary biliary cholangitis, and significantly reduces quality of life","volume":"49","author":"Hegade","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B7","first-page":"914","article-title":"Systematic review: the role of ileal bile acid transporter inhibition in the management of cholestatic pruritus","volume":"55","author":"Hegade","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/nejmoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol"},{"key":"B11","first-page":"669","article-title":"Mechanisms of the anticholestatic effects of fibrates in primary biliary cholangitis","volume":"76","author":"Honda","year":"2022","journal-title":"J. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/nejmoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Serum autotaxin is massively increased in pruritus of cholestasis, but decreased after rifampicin treatment","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.29717","article-title":"Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing disease natural history","volume":"67","author":"Murillo Perez","year":"2018","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/nejmoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B24","first-page":"1885","article-title":"Triple therapy with ursodeoxycholic acid, bezafibrate, and obeticholic acid in primary biliary cholangitis: a proof-of-concept study","volume":"20","author":"Reig","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"CD011648","DOI":"10.1002\/14651858.CD011648.pub2","article-title":"Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis","volume":"3","author":"Saffioti","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B28","article-title":"FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis due to risk of serious liver injury","year":"2021","journal-title":"FDA Drug Saf. Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J. Hepatol."},{"key":"B30","first-page":"321","article-title":"Impact of seladelpar on quality of life in patients with primary biliary cholangitis: patient-reported outcomes from the RESPONSE trial","volume":"167","author":"Younossi","year":"2024","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1161358","DOI":"10.3389\/fphar.2023.1161358","article-title":"Comparative efficacy and safety of interventions for primary biliary cholangitis: a systematic review and network meta-analysis","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1859342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:24:34Z","timestamp":1787545474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1859342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":31,"alternative-id":["10.3389\/fphar.2026.1859342"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1859342","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1859342"}}